From the blog

Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy

Published: July 5, 2006

Primary Outcome Measures:

  • Survival analysis and response to anti-cancer therapy [ Time Frame: At each follow-up (3 months, 6 months, 1 year; at discretion of MD) 2- Safety Issue?- No ] [ Designated as safety issue: No ]

Detailed Description:

This is a blood serum collection study at Stanford University for patients with cancer at a variety of disease sites. The purpose of this study is to collect and store blood serum from patients before, during, and after anti-cancer therapy to find new biomarkers that signal disease or response to anti-cancer therapy. The collection and analysis of these biomarkers may lead to improved diagnostic and treatment therapies for certain cancers in the future. We are also interested in collecting blood serum from healthy individuals such as the spouses, relatives, and friends of cancer patients to obtain healthy controls for comparison.


Inclusion Criteria:- Over age 18, no maximum age limit
  • Prior diagnosis of cancer (unless healthy control)
  • Karnofsky performance status of greater than 70
  • Standard pre-treatment evaluation
  • Negative pregnancy test
  • Signed informed consent
Exclusion Criteria:- Less than 18 years old
  • Patient without cancer (unless healthy control)
Contact Us
Have you received a diagnosis? *